Halozyme Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Halozyme Therapeutics heeft een totaal eigen vermogen van $452.7M en een totale schuld van $1.5B, wat de schuld-eigenvermogensverhouding op 332.3% brengt. De totale activa en totale passiva bedragen respectievelijk $2.1B en $1.7B. De EBIT Halozyme Therapeutics is $477.0M waardoor de rentedekking 60.1 is. Het heeft contanten en kortetermijnbeleggingen van $666.3M.
Belangrijke informatie
332.3%
Verhouding schuld/eigen vermogen
US$1.50b
Schuld
| Rente dekkingsratio | 60.1x |
| Contant | US$666.31m |
| Aandelen | US$452.70m |
| Totaal verplichtingen | US$1.67b |
| Totaal activa | US$2.12b |
Recente financiële gezondheidsupdates
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Recent updates
Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29Halozyme Therapeutics: Behind The Pullback
Oct 22Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $1.1B ) HALO } overtreffen de korte termijn passiva ( $108.8M ).
Langlopende schulden: De kortetermijnactiva van HALO ( $1.1B ) dekken de langetermijnschulden ( $1.6B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 185.1% ) HALO wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van HALO is de afgelopen 5 jaar gestegen van 26% naar 332.3%.
Schuldendekking: De schuld van HALO wordt goed gedekt door de operationele kasstroom ( 26.8% ).
Rentedekking: De rentebetalingen op de schuld van HALO worden goed gedekt door EBIT ( 60.1 x dekking).